Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

Eligibility Criteria

• * Men and women \>= 18 years of age
• * Patients must have histologically identified chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) as defined by the World Health Organization (WHO) classification of hematopoietic neoplasms
• * Treatment naive CLL/SLL; No prior therapy for CLL/SLL, including chemotherapy and/or radiotherapy is allowed
• * Estimated life expectancy of greater than 24 months
• * Patients with neutropenic (granulocyte \[PMN\]s \< 500 cells/mm\^3) or having received rituximab within 6 months
• * Patients with fever (temperature \> 38 degrees Celsius \[C\]) within 1 week
• * Active infection, recent infection requiring systemic treatment that was completed =\< 14 days before starting treatment on the study
• * Patients with known human immunodeficiency virus (HIV) infection
• * History of allergic reactions attributable to compounds of similar chemical or biologic composition to any component of pneumococcal vaccines
• * Chemotherapy in 4 weeks or received Rituximab or similar anti CD20 monoclonal antibody for non-hematological indications within 6 months
• * Received intravenous immunoglobulin (IVIG) within 3 months prior to vaccination
• * History of allogenic stem cell transplantation
• * Patients who have received cellular therapy (e.g. CAR-T cells) within 12 months prior to vaccination
• * Patients who have previously received pneumococcal vaccine within the preceding 12 months
• * Absolute lymphocyte count less than 500 cells/mm\^3
• * Patient with other severe immune deficiency
• * Patients may not be receiving any other investigational agents
• * Active malignancy from which the subject is considered by his or her physician to have a less than 5-year survival expectation
• * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection and/or psychiatric illness/social situations that would limit compliance with study requirements
• * Concurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc., or chronic administration \[\> 14 days\] of \> 20 mg/day of prednisone) within 14 days of the first dose of study drug
• * Because of the potential for H2-blockers to modulate antibody response to pneumococcal vaccine, patients must discontinue treatment with H2-blockers (cimetidine, ranitidine, etc.) prior to beginning protocol therapy
• * Unwilling or unable to participate in all required study evaluations and procedures
• * Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations)